2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Thyroid Neoplasms
3
Prostatic Neoplasms
3
Lung Neoplasms
3
Uterine Cervical Neoplasms
2
Stomach Neoplasms
2
Sarcoma, Synovial
2
Sarcoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Liposarcoma
2
Leukemia, Myeloid, Acute
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Tongue Neoplasms
1
Tobacco Use Disorder
1
Thyroid Nodule
1
Thymus Neoplasms
1
Testicular Neoplasms
1
Skin Neoplasms
1
Sarcoma, Kaposi
1
Salivary Gland Neoplasms
1
Interventions
Gemcitabine
13
pembrolizumab
9
Specimen Handling
9
enfortumab vedotin
8
Cisplatin
8
Magnetic Resonance Spectroscopy
7
avelumab
5
Carboplatin
5
vinflunine
4
Nivolumab
4
atezolizumab
3
Immunoglobulin G
3
Disulfides
3
Biopsy
3
eribulin
2
cabozantinib
2
Standard of Care
2
Ramucirumab
2
Radiotherapy
2
Platinum
2
Nephroureterectomy
2
Ipilimumab
2
Doxorubicin
2
Docetaxel
2
CTLA-4 Antigen
2
Bortezomib
2
1,2-diaminocyclohexaneplatinum II citrate
2
vandetanib
1
tremelimumab
1
tocilizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ureteral Neoplasms
×
Molecular Diagnostic Techniques
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled